PT - JOURNAL ARTICLE AU - Tsallos, Dimitrios AU - Ikonen, Nemo AU - Miettinen, Juho J. AU - Majumder, Muntasir Mamun AU - Eldfors, Samuli AU - Västrik, Imre AU - Parsons, Alun AU - Suvela, Minna AU - Dunphy, Katie AU - Dowling, Paul AU - Bazou, Despina AU - O’Gorman, Peter AU - Lievonen, Juha AU - Silvennoinen, Raija AU - Anttila, Pekka AU - Heckman, Caroline A. TI - Multi-omic and functional screening reveal targetable vulnerabilities in <em>TP53</em> mutated multiple myeloma AID - 10.1101/2024.08.23.24312359 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.23.24312359 4099 - http://medrxiv.org/content/early/2024/08/23/2024.08.23.24312359.short 4100 - http://medrxiv.org/content/early/2024/08/23/2024.08.23.24312359.full AB - Despite development of several effective therapies for multiple myeloma (MM), the prognosis of patients with partial deletion of chromosome 17 (del(17p)) and TP53 aberrations remains poor. By applying comprehensive multi-omics profiling analyses (whole exome and transcriptome sequencing plus proteomics) and functional ex vivo drug screening to samples from 167 patients with MM, we uncovered novel therapeutic vulnerabilities specific to TP53 mutated MM. Our findings revealed a distinct sensitivity profile to a range of inhibitors (mitotic, topoisomerase, HDAC, HSP90, IGF1R and PI3K/AKT/mTOR inhibitors) irrespective of 17p deletion status. Conversely, no increase in sensitivity was observed for monoallelic TP53 (del(17p) with WT TP53) when compared to other samples, highlighting the remaining unmet clinical need. Notably, plicamycin, an RNA synthesis inhibitor linked to modulation of chromatin structure and increased transcription, emerged as particularly eXicacious for TP53 mutated MM. The increased sensitivity correlated with higher protein expression of the drug targets: HDAC2, HSP90AA1 and multiple ribosomal subunits. Additionally, we observed increased RNA expression of G2M checkpoint, E2F targets and mTORC1 signaling in our cohort and the MMRF-CoMMpass (NCT01454297) study in TP53 mutated MM. Harmonization of multi-omics data with ex vivo drug screening results revealed that TP53 mutated MM is functionally distinct from MM with monoallelic TP53, and demonstrates that MM with mutated TP53, with and without del(17p), may be targetable by approved drugs. These results further indicate the need for regular monitoring by sequencing to identify these patients.KEY POINTS TP53 mutation in myeloma confers sensitivity to multiple compounds, including approved drugs, irrespective of del(17p) status.TP53 mutated myeloma links to higher expression of drug targets involved in cell proliferation, mRNA processing, and chromatin modulation.Competing Interest StatementC.A.H has received funding from BMS/Celgene, Kronos Bio, Novartis, Oncopeptides, WNTResearch, and Zentalis Pharmaceuticals for research unrelated to this work, and honorarium from Amgen and Autolus. R.S. has received research funding from Amgen, BMS/Celgene and Takeda administered by Hospital Science Centers, unrelated to this work. All other authors declare no conflicts of interest.Funding StatementThe project was supported by grants from the Sigrid Juselius Foundation, Cancer Foundation of Finland, and Research Council of Finland (grants 334781, 320185, 352265, and 357686) to C.A.H. D.T. was supported by the University of Helsinki Doctoral Program of Biomedicine and personal grants from the Cancer Foundation of Finland and the Finnish Cultural Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by an ethical advisory committee of the Helsinki University Hospital and Comprehensive Cancer Center (239/13/03/00/2010 and 303/13/03/01/2011). The patients provided informed consent for the use of their samples and data, and the samples were taken using approved protocols and in accordance with the Declaration of Helsinki. The patients were anonymized prior to receiving their samples and their data securely handled according to GDPR standards.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe ex vivo drug sensitivity, DNA sequencing, RNA sequencing, and proteomic data generated in this study will be deposited in the Zenodo public repository upon acceptance of the manuscript for publication. Additionally, this study was supplemented with publicly available data from the Multiple Myeloma Research Foundation Researcher Gateway (https://research.themmrf.org/).